n-Methyl-1,6-dihydronicotinamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: n-Methyl-1,6-dihydronicotinamide
• 英文别名: N-methyl-1,2-dihydropyridine-5-carboxamide
• 化学式: C₇H₁₀N₂O
• 分子量: 138.17
• InChiKey: XLSBOYLWETVJCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• INJECTABLE IMPLANTS FOR TISSUE AUGMENTATION AND RESTORATION
  申请人：BIOELASTICS RESEARCH, LTD.

  公开号：EP1056413A1

  公开（公告）日：2000-12-06
• EP1056413A4
  申请人：——

  公开号：EP1056413A4

  公开（公告）日：2003-08-20
• BIOELASTOMER NANOMACHINES AND BIOSENSORS
  申请人：BIOELASTICS RESEARCH, LTD.

  公开号：EP1297010A2

  公开（公告）日：2003-04-02
• ENGINEERED PROTEINS, AND METHODS OF MAKING AND USING
  申请人：TIRRELL DAVID A.

  公开号：US20100233242A1

  公开（公告）日：2010-09-16

  The present invention provides engineered proteins and biomedical products made from the engineered proteins. The biomedical products include lenses useful for ophthalmic purposes.
• COMPOSITIONS AND METHODS FOR OPTIMIZING DRUG HYDROPHOBICITY AND DRUG DELIVERY TO CELLS
  申请人：URRY DAN W.

  公开号：US20100330606A1

  公开（公告）日：2010-12-30

  Methods to determine drug hydrophobicity and to quantify changes in drug hydrophobicity that optimize drug function by means of differential scanning calorimetry of an endothermic phase transition of a base protein-based polymer, specifically of an elastic-contractile model protein, to which is attached the drug to be evaluated for its hydrophobicity in terms of the change in Gibbs free energy for hydrophobic association, ΔG HA have been developed. Also described herein is the preparation of nanoparticles comprised of protein-based polymers, specifically of elastic-contractile model proteins, designed for the binding and desired release rate of a specific drug or class of drugs. Further described herein is a means of targeting the drug-laden nanoparticle to a cell by means of decorating the nanoparticle surface with a molecular entity that selectively binds to the diseased cell or disease causing organism, e.g., by decorating the drug-laden nanoparticle surface with synthetic antigen-binding fragment to an up-regulated receptor characteristic of the diseased cell.